Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-DUAL PCI
NCT02164864Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 41
01
Overview
A Phase 3 trial of dabigatran in Atrial fibrillation (AFib), sponsored by Boehringer Ingelheim. Started Jul 2014; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02164864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164864.